About Catabasis Pharmaceuticals

Catabasis is a clinical stage biotechnology company with a robust portfolio of investigational new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases. The company's drug development programs are rooted in the principles of Pathway Pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its SMART (Safely Metabolized And Rationally Targeted) linker technology, we conjugate two drugs that act on different components of a disease pathway to produce new chemical entities with improved safety, tolerability and significantly enhanced efficacy. This approach has allowed Catabasis to move rapidly from concept to investigational new drug (IND) application, and to produce new medicines with superior efficacy.